---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216929"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-05-11T20:33:41+00:00"
generated_at: "2026-05-11T20:40:36.799703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q1 2026 revenue $149.4M; FIRDAPSE up 18%, AGAMREE up 67% YoY

## Summary
- Product revenue net $149.3M for Q1 2026, up 5.6% YoY from $141.4M.
- FIRDAPSE net revenue $98.9M (+18% YoY); AGAMREE $36.7M (+67%); FYCOMPA $13.8M (-61%).
- GAAP net income $63.7M ($0.52 basic EPS); non-GAAP net income $100.3M ($0.82 basic EPS).
- Cash & equivalents $755.9M at March 31, 2026, up from $709.2M; no funded debt.
- No forward guidance or updated FY2026 outlook provided in the release.

## SEC filing metadata
- accession: 0001193125-26-216929
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-05-11T20:33:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/0001193125-26-216929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/d845745d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216929
- JSON: https://secwatch.observer/filing/0001193125-26-216929.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.